SCHEMBL3372013

SCHEMBL3372013

Cc1c(-c2ccccc2)nc(N)c(C#N)c1-c1ccc(Cl)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.69
ADORA2A P29274 5/20 0.66
HSD17B10 Q99714 4/20 0.66
HTT P42858 3/20 0.66
ADRA2A P08913 1/20 0.66
ALDH1A1 P00352 6/20 0.64
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
HPGD P15428 4/20 0.64
CASP1 P29466 1/20 0.64
BLM P54132 1/20 0.64
MAPT P10636 4/20 0.58
ADORA1 P30542 4/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
MAPK1 P28482 2/20 0.54
LMNA P02545 1/20 0.54
ALOX15 P16050 1/20 0.54
CYP1A2 P05177 1/20 0.54
GAA P10253 1/20 0.54
CYP2C9 P11712 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31139645 0.88 BRD4 (0.59) KDM4EADORA2AHSD17B10HTTADRA2A
SCHEMBL27903042 0.88 KDM4E (0.67) KDM4EADORA2AHSD17B10HTTADRA2A
SCHEMBL3370683 0.84 KDM4E (0.59) KDM4EADORA2AHSD17B10HTTADRA2A
SCHEMBL5483521 0.81 KDM4E (0.64) KDM4EADORA2AHSD17B10HTTADRA2A
SCHEMBL30656203 0.79 ADORA1 (0.59) KDM4EADORA2AHSD17B10HTTMEN1
SCHEMBL26632974 0.79 ADORA1 (0.59) KDM4EADORA2AHSD17B10HTTMEN1
SCHEMBL31139640 0.78 KDM4E (0.58) KDM4EADORA2AHSD17B10HTTALDH1A1
SCHEMBL3369015 0.78 DPP4 (0.63) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL6255086 0.78 ALDH1A1 (1.00) KDM4EADORA2AHSD17B10HTTADRA2A
SCHEMBL31139637 0.78 KDM4E (0.69) KDM4EADORA2AHSD17B10HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 KDM4E 1329/4885ADORA2A 794/4885HSD17B10 1818/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK KDM4E 916/4885ADORA2A 547/4885HSD17B10 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.